8-K: Adicet Bio Gets Nasdaq Extension, Moves to Capital Market

Adicet Bio, Inc. received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, resulting in a transfer to the Nasdaq Capital Market.

Summary

• Adicet Bio, Inc. (ACET) received an Extension Notice from Nasdaq on October 7, 2025, granting an additional 180 calendar days, until April 6, 2026, to regain compliance with the minimum $1.00 bid price requirement.
• The company was previously notified on April 7, 2025, that its common stock bid price had been below $1.00 for 30 consecutive business days, with an initial compliance deadline of October 6, 2025.
• In connection with the extension, the listing of Adicet Bio's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025.
• Adicet Bio intends to actively monitor its common stock bid price and consider options, including a reverse stock split, to resolve the deficiency and regain compliance.
• Compliance will be regained if the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days before April 6, 2026.
• There is no assurance that the company will regain compliance or avoid delisting from Nasdaq.

Sentiment

Score: 4

Explanation: While an extension was granted, the company failed to meet the initial Nasdaq bid price requirement, leading to a market transfer and continued uncertainty regarding delisting. The underlying issue remains unresolved.

Positives

• Adicet Bio received an additional 180-day extension, until April 6, 2026, to regain compliance with Nasdaq's minimum bid price requirement, avoiding immediate delisting.

Negatives

• The company failed to meet the initial Nasdaq minimum bid price requirement by the October 6, 2025 deadline.
• The common stock listing will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025, which is generally considered a lower tier market.
• There is no assurance that Adicet Bio will regain compliance with the bid price requirement or that its common stock will not be delisted from Nasdaq.
• The company may need to effect a reverse stock split, which can be dilutive and often viewed negatively by investors, to regain compliance.

Risks

• Inability to regain compliance with Nasdaq's minimum bid price requirement, leading to potential delisting.
• The effect of global economic conditions and public health crises on the company's business and financial results, including disruptions to preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital.
• Inability to execute on its strategy, including obtaining requisite regulatory approvals on expected timelines, if at all.
• Positive results from preclinical or clinical studies may not be predictive of future or ongoing study results.
• Clinical studies may fail to demonstrate adequate safety and efficacy of product candidates, which could prevent, delay, or limit regulatory approval and commercialization.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• Inability to meet production and product release expectations.

Future Outlook

Adicet Bio intends to actively monitor the bid price for its common stock and will consider available options, including a reverse stock split, to resolve the deficiency and regain compliance with the Nasdaq minimum bid price requirement by April 6, 2026.

Management Comments

• We intend to continue actively monitor the bid price for our Common Stock between now and April 6, 2026, and will consider available options to resolve the deficiency and regain compliance with the Bid Price Requirement. These options include, but are not limited to, effecting a reverse stock split, if necessary, to attempt to regain compliance.

Industry Context

Nasdaq listing compliance issues, particularly related to minimum bid price, are common for smaller biotechnology companies, especially those in early development stages or facing market headwinds. The transfer to the Nasdaq Capital Market is a standard procedure for companies granted extensions, providing additional time to address compliance while maintaining a public listing, albeit on a market tier with potentially lower liquidity and visibility compared to the Global Market.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's ability to maintain its Nasdaq listing and the potential for a reverse stock split, which could impact share count and perception.
• The transfer to the Nasdaq Capital Market may affect the liquidity and visibility of the company's stock.

Next Steps

• Actively monitor the bid price for its common stock.
• Consider available options, including a reverse stock split, to resolve the bid price deficiency.
• Regain compliance with the Nasdaq minimum bid price requirement by April 6, 2026.

Key Dates

Recommendation

The company received an extension to regain Nasdaq compliance, avoiding immediate delisting. However, the underlying bid price deficiency and the transfer to the Nasdaq Capital Market indicate ongoing challenges. Investors should hold to monitor the company's progress in regaining compliance and the potential impact of a reverse stock split, while acknowledging the continued risk of delisting.

Keywords

Adicet Bio, ACET, Nasdaq, Listing Compliance, Bid Price Rule, Delisting Risk, Reverse Stock Split, Nasdaq Capital Market